MedTrace Logo

Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma

NCT05654896 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2022-12-16

No results posted yet for this study

Summary

This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess.

There would be two comparison groups. Current standard of care treatment at PKLI\&RC (as per local guidelines) would be given to all patients receiving TACE for the intervention group or 'antibiotic group' (i.e., Inj. Ceftriaxone 1g, intravenous × stat). While no antibiotic would be given to the 'no antibiotic group'.

Conditions

  • Antibiotic Prophylaxis

Interventions

DRUG

Ceftriaxone Sodium

Antibiotic will be administered prophylactically for TACE

Sponsors & Collaborators

  • Ahmad Zia

    collaborator UNKNOWN

  • Muhammad Junaid Tahir

    collaborator UNKNOWN

  • Nadeem Iqbal

    lead OTHER

Principal Investigators

  • Ahmad Zia Ud Din · PKLI & RC, Lahore

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-26
Primary Completion
2023-11-26
Completion
2023-12-26

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05654896 on ClinicalTrials.gov